Printed flexible plastic microchip for viral load measurement through quantitative detection of viruses in plasma and saliva

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Shafiee, Hadi ^a,b   Kanakasabapathy, Manoj Kumar ^a,b   Juillard, Franceline ^c   Keser, Mert ^a,b   Sadasivam, Magesh ^a,b   Yuksekkaya, Mehmet ^a,b   Hanhauser, Emily ^c   Henrich, Timothy J ^c   Kuritzkes, Daniel R ^c   Kaye, Kenneth M ^c   Demirci, Utkan ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HIV INFECTIONS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LAB ON A CHIP; PHYSIOLOGY; POINT OF CARE SYSTEM; STANDARD; STANDARDS; VIROLOGY; VIRUS LOAD;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; LAB-ON-A-CHIP DEVICES; POINT-OF-CARE SYSTEMS; REFERENCE STANDARDS; VIRAL LOAD;

EID: 84930672194     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09919     Document Type: Article

References (93)

1. Yetisen, A. K., Akram, M. S. & Lowe, C. R. Paper-based microfluidic point-of-care diagnostic devices. Lab. Chip. 13, 2210-2251 (2013).
2. Shafiee, H., Caldwell, J. L., Sano, M. B. & Davalos, R. V. Contactless dielectrophoresis: a new technique for cell manipulation. Biomed. Microdevices 11, 997-1006 (2009).
3. Shafiee, H., Sano, M. B., Henslee, E. A., Caldwell, J. L. & Davalos, R. V. Selective isolation of live/dead cells using contactless dielectrophoresis (cDEP). Lab. Chip. 10, 438-445 (2010).
4. Shafiee, H. et al. Emerging technologies for point-of-care management of HIV infection. Annu. Rev. Med. 66, 14.1-14.19 (2014).
5. Wang, S., Xu, F. &Demirci, U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv. 28, 770-781 (2010).
6. Wang, S. et al. Efficient on-chip isolation of HIV subtypes. Lab. Chip. 12, 1508-1515 (2012).
7. Tokel, O., Inci, F. & Demirci, U. Advances in plasmonic technologies for point of care applications. Chem. Rev. 114, 5728-5752 (2014).
8. Shafiee, H. et al. Nanostructured optical photonic crystal biosensor for HIV viral load measurement. Sci. Rep. 4, e4116 (2014).
9. Shafiee, H. et al. Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 9, 2553-2563 (2013).
10. Inci, F. et al. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS. Nano 7, 4733-4745 (2013).
11. Whitesides, G. M. Cool, or simple and cheap? Why not both? Lab. Chip. 13, 11-13 (2013).
12. Blow, N. Microfluidics: the great divide. Nat. Methods 6, 683-686 (2009).
13. World Health Organization, The use of antiretroviral drugs for treatment and preventingHIV infection, (2013). Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf?ua51. Date of access: 28/08/2014.
14. Martinez, A. W., Phillips, S. T., Whitesides, G. M. & Carrilho, E. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal. Chem. 82, 3-10 (2010).
15. Schilling, K. M., Lepore, A. L., Kurian, J. A. & Martinez, A. W. Fully enclosed microfluidic paper-based analytical devices. Anal. Chem. 84, 1579-1585 (2012).
16. Martinez, A. W. Microfluidic paper-based analytical devices: from POCKET to paper-based ELISA. Bioanalysis 3, 2589-2592 (2011).
17. Cheng, C. M. et al. Paper-based ELISA. Angew. Chem. Int. Ed. Engl. 49, 4771-4774 (2010).
18. Ellerbee, A. K. et al. Quantifying colorimetric assays in paper-based microfluidic devices by measuring the transmission of light through paper. Anal. Chem. 81, 8447-8452 (2009).
19. Martinez, A. W., Phillips, S. T., Wiley, B. J., Gupta, M. & Whitesides, G. M. FLASH: a rapid method for prototyping paper-based microfluidic devices. Lab. Chip. 8, 2146-2150 (2008).
20. Martinez, A. W. et al. Simple telemedicine for developing regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal. Chem. 80, 3699-3707 (2008).
21. Annels, N. E. et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin. Infect. Dis. 42, 1743-1748 (2006).
22. Koelle, D. M. et al. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J. Infect. Dis. 176, 94-102 (1997).
23. Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310 (1986).
24. Bland, J. M.&Altman, D. G. Measuring agreement inmethod comparison studies. Stat. Methods Med. Res. 8, 135-160 (1999).
25. Hong, J. et al. AC frequency characteristics of coplanar impedance sensors as design parameters. Lab Chip. 5, 270-279 (2005).
26. Rouet, F. et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol 43, 2709-2717 (2005).
27. Deeks, S. G. et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614 (2012).
28. World Health Organization. Antiretroviral therapy in low-and middle-income countries by region. Available at: http://www.who.int/hiv/topics/treatment/data/ en/. Date of access: 28/08/2014. (2011).
29. Marconi, V. C. et al. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery andAIDS. PLoS. One 6, e17956 (2011).
30. World Health Organization, March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, Available at: http://www.who.int/hiv/pub/guidelines/arv2013/ arvs2013upplement-march2014/en/. (2014).
31. Stevens, G., Rekhviashvili, N., Scott, L. E., Gonin, R. & Stevens, W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol. 43, 857-861 (2005).
32. Schupbach, J. Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int. Arch.Allergy Immunol. 132, 196-209 (2003).
33. Labib, M., Shipman, P. O.,Martic, S. & Kraatz, H. B. Towards an early diagnosis of HIV infection: an electrochemical approach for detection of HIV-1 reverse transcriptase enzyme. Analyst 136, 708-715 (2011).
34. van Oosterhout, J. J. G. et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop. Med. Int. Health 14, 856-861 (2009).
35. Mee, P., Fielding, K. L., Charalambous, S., Churchyard, G. J. & Grant, A. D. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 22, 1971-1977 (2008).
36. Calmy, A. et al.HIV viral load monitoring in resource-limited regions: optional or necessary? Clin. Infect. Dis. 44, 128-134 (2007).
37. Stevens, W. S., Scott, L. E. & Crowe, S. M. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J. Infect. Dis. 201, S16-26 (2010).
38. Tanriverdi, S., Chen, L. & Chen, S. A rapid and automated sample-to-result HIV load test for near-patient application. J. Infect. Dis. 201, S52-58 (2010).
39. Usdin, M., Guillerm, M. & Calmy, A. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J. Infect. Dis. 201, S73-77 (2010).
40. World Health Organization. Guidance on provider-initiated HIV testing and counselling in health facilities. Available at: http://whqlibdoc.who.int/ publications/2007/9789241595568-eng.pdf. Date of access: 28/08/2014.
41. Keiser, O. et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 23, 1867-1874 (2009).
42. Lynen, L., Van Griensven, J. & Elliott, J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr. Opin. HIV. AIDS. 5, 1-5 (2010).
43. Balakrishnan, P. et al. Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J. Med. Res. 134, 823-834 (2011).
44. Damania, B., Lee, H. & Jung, J. U. Primate herpesviral oncogenes. Mol. Cells. 9, 345-349 (1999).
45. Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDSassociated Kaposi's sarcoma. Science 266, 1865-1869 (1994).
46. Moore, P. S.&Chang, Y. Detection of herpesvirus-likeDNAsequences in Kaposi's sarcoma in patients with and without HIV infection. New Engl. J. Med. 332, 1181-1185 (1995).
47. Chang, Y. et al. Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. Arch. Intern. Med. 156, 202-204 (1996).
48. Said, J. W. et al. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 88, 3124-3128 (1996).
49. Jones, D. et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiactransplant recipient. New Engl. J. Med. 339, 444-449 (1998).
50. Kikuta,H., Itakura, O., Taneichi, K.&Kohno, M. Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease. Brit. J. Haematol. 99, 790-793 (1997).
51. Soulier, J. et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86, 1276-1280 (1995).
52. Wabinga, H. R., Parkin, D.M., Wabwire-Mangen, F. & Mugerwa, J. W. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int. J. Cancer 54, 26-36 (1993).
53. Athale, U. H., Patil, P. S., Chintu, C. & Elem, B. Influence of HIV epidemic on the incidence of Kaposi's sarcoma in Zambian children. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 8, 96-100 (1995).
54. Antman, K. & Chang, Y. Kaposi's sarcoma. N. Engl. J. Med. 342, 1027-1038 (2000).
55. Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1, 702-703 (1964).
56. Johansson, B., Klein, G., Henle, W. & Henle, G. Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int. J. Cancer. 6, 450-462 (1970).
57. zur Hausen, H. et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058 (1970).
58. Ho, M. et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J. Infect. Dis. 152, 876-886 (1985).
59. Rickinson, A. B., E. Kieff Epstein-Barr virus: In fields virology, 5th edition, edited by Fields BN, Knipe DM, Howley. Lippincott-Williams & Wilkins Publishers: Philadelphia, PA. 2655-2700 (2007).
60. Casper, C. et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J. Infect. Dis. 195, 30-36 (2007).
61. de Franca, T. R., de Araujo, R. A., Ribeiro, C. M. & Leao, J. C. Salivary shedding of HHV-8 in people infected or not by human immunodeficiency virus 1. J. Oral. Pathol. Med. 40, 97-102 (2011).
62. Mbulaiteye, S. M. et al. Detection of kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J. Infect. Dis. 190, 1382-1386 (2004).
63. Laney,A. S. et al.Human herpesvirus 8 presence and viral load are associatedwith the progression of AIDS-associated Kaposi's sarcoma. AIDS. 21, 1541-1545 (2007).
64. Quinlivan, E. B. et al. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J. Infect. Dis. 185, 1736-1744 (2002).
65. Rooney, C. M. et al. Early identification of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease. Brit. J. haematol. 89, 98-103 (1995).
66. Riddler, S. A., Breinig, M. C. & McKnight, J. L. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84, 972-984 (1994).
67. Savoie A, P. C., Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant recipients and risk of lymphoproliferative disease. Blood 83, 2715-2722 (1994).
68. Stevens, S. J. et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97, 1165-1171 (2001).
69. Salmanzadeh, A. et al. Isolation of prostate tumor initiating cells (TICs) through their dielectrophoretic signature. Lab. Chip. 12, 182-189 (2012).
70. Salmanzadeh, A., Sano, M. B., Shafiee, H., Stremler, M. A. & Davalos, R. V. Isolation of rare cancer cells from blood cells using dielectrophoresis. Conf. Proc. IEEE. Eng. Med. Biol. Soc. 2012, 590-593 (2012).
71. Martinez, A. W., Phillips, S. T., Butte, M. J.&Whitesides, G. M. Patterned Paper as a Platform for Inexpensive, Low-Volume, Portable Bioassays. Angew. Chem. Int. Ed. 46, 2 (2007).
72. AS,D. et al. Top ten biotechnologies for improving health in developing countries. Nat. Genet. 32, 3 (2002).
73. Yager, P. et al. Microfluidic diagnostic technologies for global public health. Nature 442, 412-418 (2006).
74. Solomon, A. W. et al. A diagnostics platform for the integrated mapping, monitoring, and surveillance of neglected tropical diseases: rationale and target product profiles. PLoS. Negl. Trop. Dis. 6, e1746 (2012).
75. Bruzewicz, D. A., Reches, M. & Whitesides, G. M. Low-cost printing of poly(dimethylsiloxane) barriers to define microchannels in paper. Anal. Chem. 80, 3387-3392 (2008).
76. Abe, K., Suzuki, K. & Citterio, D. Inkjet-printed microfluidic multianalyte chemical sensing paper. Anal. Chem. 80, 6928-6934 (2008).
77. Li, X., Tian, J., Nguyen, T.& Shen, W. Paper-based microfluidic devices by plasma treatment. Anal. Chem. 80, 9131-9134 (2008).
78. Lu, Y., Shi, W., Jiang, L., Qin, J. & Lin, B. Rapid prototyping of paper-based microfluidics with wax for low-cost, portable bioassay. Electrophoresis 30, 1497-1500 (2009).
79. Carrilho, E.,Martinez, A. W. &Whitesides, G. M. Understanding wax printing: a simple micropatterning process for paper-based microfluidics. Anal. Chem. 81, 7091-7095 (2009).
80. Crombie, R. et al. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. J. Exp. Med. 187, 25-35 (1998).
81. Malamud, D., Davis, C., Berthold, P., Roth, E. & Friedman, H. Human submandibular saliva aggregates HIV. AIDS Res. Hum. Retrov. 9, 633-637 (1993).
82. Fox, P. C.,Wolff, A., Yeh, C. K., Atkinson, J. C. & Baum, B. J. Saliva inhibits HIV-1 infectivity. J. Am. Dent. Assoc. 116, 635-637 (1988).
83. Alsip, G. R., Ench, Y., Sumaya, C. V. & Boswell, R. N. Increased Epstein-Barr virus DNA in oropharyngeal secretions from patients with AIDS, AIDS-related complex, or asymptomatic human immunodeficiency virus infections. J. Infect. Dis. 157, 1072-1076 (1988).
84. LaDuca, J. R. et al. Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids. J. Infect. Dis. 178, 1610-1615 (1998).
85. Pauk, J. et al.Mucosal Shedding of HumanHerpesvirus 8 inMen. New Eng. J.Med. 343, 1369-1377 (2000).
86. Su, H. & Boackle, R. J. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva. Mol. Immunol. 28, 811-817 (1991).
87. Taraboletti, G., Roberts, D., Liotta, L. A. & Giavazzi, R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. cell. biol. 111, 765-772 (1990).
88. Campbell, T. B. et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS. 14, 2109-2116 (2000).
89. Kalichman, S. C., Di Berto, G. & Eaton, L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex. Transm. Dis. 35, 55-60 (2008).
90. Bourlet, T. et al. Compartmentalization of HIV-1 according to antiretroviral therapy: viral loads are correlated in blood and semen but poorly in blood and saliva. AIDS. 15, 284-285 (2001).
91. Moon, S. et al. Enumeration of CD41 T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS. ONE 6, e21409 (2011).
92. Myoung, J., Ganem, D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: Maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174, 12-21 (2011).
93. Miller, G., Shope, T., Lisco, H., Stitt, D. & Lipman, M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. U. S. A. 69, 383-387 (1972).